Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer

European Journal of Cancer

Volumn 38, Issue 5, 2002, Pages 661-666

  Taeb, J ^a,c   Artru, P ^a   Baujat, B ^b   Mabro, M ^a   Carola, E ^a   Maindrault, F ^a   Tournigand, C ^a   Krulik, M ^a   Louvet, C ^a   De Gramont, A ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Groupe Hospitalier   (France)

Author keywords

5 Fluorouracil; Chemotherapy; Cisplatin; Hydroxyurea; Metastatic Oesophageal carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA;

ADULT; AGED; ARTICLE; BIOLOGICAL MONITORING; BODY WEIGHT; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DIARRHEA; DISEASE COURSE; DRUG INFUSION; DYSPHAGIA; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; MALE; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEGLUTITION DISORDERS; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0036202477     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00400-2     Document Type: Article

References (25)

1. Oesophageal cancer treatment: Studies, strategies and facts
2. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell carcinoma of the oesophagus
3. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus
4. Chemotherapy in esophageal cancer
5. Esophageal cancer: Results of an American college of surgeons patient care evaluation study
6. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: Results and commentary
7. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous-cell oesophageal cancer
8. Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma
9. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with twice-monthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
10. High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer
11. Factors modifying cytotoxicity induced by 5-FU and hydroxyurea
12. Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer
13. Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: Summary of an in vitro model and initial clinical pilot experience
14. The cellular interaction of 5-fluorouracil and cisplatin in an human colon carcinoma cell line
15. Advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil and cisplatin (HLFP regimen)
16. Clinical benefit with cisplatin, hydroxyurea and 5-fluorouracil/leucovorin in advanced pancreatic carcinoma
17. A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer
18. Reporting results of cancer treatment
19. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer
20. Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction
21. A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma
22. A phase II trial of topotecan in esophageal carcinoma: A Southwest Oncology Group study (SWOG 9339)
23. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus
24. Preliminary results of a phase II study with Taxotere (docetaxel) in patients with primary untreated or recurrent oesophagus cancer
25. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus